Related Experiment Video
Updated: May 3, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Advances in the treatment of IDH-mutant gliomas
Chooyoung Baek1, Alice Laurenge1,2, Mehdi Touat1,2,3
1Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université.
Purpose Of Review:
Isocitrate dehydrogenase (IDH) mutation is a defining molecular driver of WHO grade 2-4 astrocytomas and oligodendrogliomas. In this article, we review the recent therapeutic approaches specifically targeting IDH-mutant gliomas and summarize ongoing clinical trials in this population.
Recent Findings:
The IDH inhibitor vorasidenib recently demonstrated its efficacy after surgical resection in grade 2 IDH-mutated gliomas. Several studies in patients with IDH-mutant gliomas are currently exploring various strategies to target IDH mutations, including the use of small-molecule inhibitors, immunotherapies, peptide vaccines and agents targeting metabolic and epigenomic vulnerabilities.
Summary:
Mutant-IDH targeting holds significant promise in treating progressive or recurrent IDH-mutant gliomas. Recent results with IDH inhibitors will change practice and influence the existing guidelines in a near future.
Insights
Targeting isocitrate dehydrogenase (IDH) mutations shows promise for treating IDH-mutant gliomas. Recent IDH inhibitor studies, like vorasidenib, are poised to impact clinical practice and guidelines for these brain tumors.
Area of Science:
- Neuro-oncology
- Molecular oncology
- Translational research
Background:
- Isocitrate dehydrogenase (IDH) mutations are key drivers in WHO grade 2-4 astrocytomas and oligodendrogliomas.
- Targeting these specific mutations represents a significant therapeutic strategy for gliomas.
Purpose of the Study:
- To review current therapeutic strategies for IDH-mutant gliomas.
- To summarize ongoing clinical trials focused on IDH-mutant glioma treatment.
Main Methods:
- Review of recent scientific literature on IDH-mutant glioma therapies.
- Analysis of ongoing clinical trials targeting IDH mutations.
Main Results:
- The IDH inhibitor vorasidenib demonstrated efficacy in grade 2 IDH-mutated gliomas post-resection.
- Ongoing trials explore small-molecule inhibitors, immunotherapies, peptide vaccines, and metabolic/epigenomic agents.
Conclusions:
- Targeting mutant-IDH offers substantial promise for progressive or recurrent IDH-mutant gliomas.
- Emerging IDH inhibitor data is expected to influence clinical practice and guidelines.
